CL2015001754A1 - Compuestos derivados de quinolina e isoquinolina; composición farmacéutica y uso para reducir el riesgo de desarrollar una enfermedad o trastorno retinal en el que la acumulación de a2e y/o lipofuscina en el tejido retinal o la señalización de vegf de las células rpe en respuesta al estrés oxidativo. - Google Patents
Compuestos derivados de quinolina e isoquinolina; composición farmacéutica y uso para reducir el riesgo de desarrollar una enfermedad o trastorno retinal en el que la acumulación de a2e y/o lipofuscina en el tejido retinal o la señalización de vegf de las células rpe en respuesta al estrés oxidativo.Info
- Publication number
- CL2015001754A1 CL2015001754A1 CL2015001754A CL2015001754A CL2015001754A1 CL 2015001754 A1 CL2015001754 A1 CL 2015001754A1 CL 2015001754 A CL2015001754 A CL 2015001754A CL 2015001754 A CL2015001754 A CL 2015001754A CL 2015001754 A1 CL2015001754 A1 CL 2015001754A1
- Authority
- CL
- Chile
- Prior art keywords
- retinal
- lipofuscin
- isoquinoline
- vegf
- quinoline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Quinoline Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261740197P | 2012-12-20 | 2012-12-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2015001754A1 true CL2015001754A1 (es) | 2015-11-06 |
Family
ID=50979217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2015001754A CL2015001754A1 (es) | 2012-12-20 | 2015-06-18 | Compuestos derivados de quinolina e isoquinolina; composición farmacéutica y uso para reducir el riesgo de desarrollar una enfermedad o trastorno retinal en el que la acumulación de a2e y/o lipofuscina en el tejido retinal o la señalización de vegf de las células rpe en respuesta al estrés oxidativo. |
Country Status (14)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11485753B2 (en) | 2012-12-21 | 2022-11-01 | Janssen Pharmaceutica Nv | Substituted nucleosides, nucleotides and analogs thereof |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1888548B1 (en) | 2005-05-26 | 2012-08-22 | Neuron Systems, Inc | Quinoline derivative for the treatment of retinal diseases |
| EP2948149A4 (en) | 2013-01-23 | 2016-12-14 | Aldeyra Therapeutics Inc | BY TOXIC ALDEHYDIC DISEASES AND TREATMENT |
| CN105228989A (zh) | 2013-01-25 | 2016-01-06 | 奥尔德拉医疗公司 | 黄斑变性治疗中的新颖捕获剂 |
| AU2016311163A1 (en) * | 2015-08-21 | 2018-04-05 | Aldeyra Therapeutics, Inc. | Aldehyde conjugates and uses thereof |
| KR102664994B1 (ko) | 2015-08-21 | 2024-05-13 | 알데이라 테라퓨틱스, 아이엔씨. | 중수소화 화합물 및 이의 용도 |
| BR112018069533A2 (pt) | 2016-02-28 | 2019-04-16 | Aldeyra Therapeutics, Inc. | tratamento de condições alérgicas oculares com ciclodextrinas |
| CN109152774A (zh) | 2016-05-09 | 2019-01-04 | 奥尔德拉医疗公司 | 眼部炎性病症和疾病的组合治疗 |
| WO2018039192A1 (en) * | 2016-08-22 | 2018-03-01 | Aldeyra Therapeutics, Inc. | Aldehyde trapping compounds and uses thereof |
| JP2020511461A (ja) | 2017-03-16 | 2020-04-16 | アルデイラ セラピューティクス， インコーポレイテッド | 多形化合物およびその使用 |
| MX2020003425A (es) | 2017-10-10 | 2020-07-29 | Aldeyra Therapeutics Inc | Tratamiento de trastornos inflamatorios. |
| US12006298B2 (en) | 2018-08-06 | 2024-06-11 | Aldeyra Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| CN115869258A (zh) | 2018-09-25 | 2023-03-31 | 奥尔德拉医疗公司 | 用于治疗干眼病的调配物 |
| JP2022526917A (ja) | 2019-03-26 | 2022-05-27 | アルデイラ セラピューティクス， インコーポレイテッド | 眼科用製剤およびその使用 |
| EP4185566A1 (en) | 2020-07-16 | 2023-05-31 | Dermavant Sciences GmbH | Isoquinoline compounds and their use in treating ahr imbalance |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2086186A (en) | 1933-10-10 | 1937-07-06 | Us Rubber Co | Treatment of rubber |
| SU509046A1 (ru) | 1975-02-21 | 1984-06-23 | Всесоюзный научно-исследовательский химико-фармацевтический институт им.Серго Орджоникидзе | Производные 2-карбэтокси-3-аминоиндола,про вл ющие противовоспалительную активность, и способ их получени |
| US4675332A (en) | 1984-12-10 | 1987-06-23 | Warner-Lambert Company | Acidic tetrazolyl substituted indole compounds and their use as antiallergy agents |
| GB8610981D0 (en) | 1986-05-06 | 1986-06-11 | Ici America Inc | Quinoline amides |
| AU641052B2 (en) | 1990-11-02 | 1993-09-09 | Aventisub Ii Inc. | 3-amidoindolyl derivatives |
| US5668117A (en) | 1991-02-22 | 1997-09-16 | Shapiro; Howard K. | Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments |
| US6444221B1 (en) | 1992-06-30 | 2002-09-03 | Howard K. Shapiro | Methods of treating chronic inflammatory diseases using carbonyl trapping agents |
| US20050090553A1 (en) | 1992-06-30 | 2005-04-28 | Shapiro Howard K. | Compositions and method for treatment of chronic inflammatory diseases |
| US5472954A (en) | 1992-07-14 | 1995-12-05 | Cyclops H.F. | Cyclodextrin complexation |
| US5493027A (en) | 1993-01-22 | 1996-02-20 | Board Of Regents, The University Of Texas System | Anticonvulsive agents and uses thereof |
| US5597823A (en) | 1995-01-27 | 1997-01-28 | Abbott Laboratories | Tricyclic substituted hexahydrobenz [e]isoindole alpha-1 adrenergic antagonists |
| CA2261916A1 (en) | 1996-08-01 | 1998-02-12 | Dowelanco Llc | 4-substituted quinoline derivatives having fungicidal activity |
| WO1998050372A1 (de) | 1997-05-02 | 1998-11-12 | Schering Aktiengesellschaft | Substituierte heterocyclen und deren verwendung in arzneimitteln |
| WO1999046237A1 (en) | 1998-03-12 | 1999-09-16 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases |
| US6498154B1 (en) | 1999-05-04 | 2002-12-24 | Wyeth | Cyclic regimens using quinazolinone and benzoxazine derivatives |
| AU1735001A (en) | 1999-12-10 | 2001-06-18 | Senju Pharmaceutical Co., Ltd. | Cyclodextrin-containing pharmaceutical composition |
| FR2827599A1 (fr) | 2001-07-20 | 2003-01-24 | Neuro3D | Composes derives de quinoleine et quinoxaline,preparation et utilisations |
| US20060014786A1 (en) | 2002-05-17 | 2006-01-19 | Rajeev Raut | Opthalmic pharmaceutical compositions and methods for treating ocular inflammation |
| CA2451267A1 (en) | 2002-12-13 | 2004-06-13 | Warner-Lambert Company Llc | Pharmaceutical uses for alpha2delta ligands |
| US20040242704A1 (en) | 2003-03-14 | 2004-12-02 | University Of Washington, Techtransfer - Invention Licensing | Stabilized mutant opsin proteins |
| US20060111318A1 (en) | 2003-04-18 | 2006-05-25 | Advanced Medicine Research Institute | Agent for treating eye diseases |
| EP2292239A3 (en) | 2003-04-18 | 2011-03-30 | Advanced Medicine Research Institute | Remedies for diseases to be applied to eye |
| US7297709B2 (en) | 2003-05-22 | 2007-11-20 | Abbott Laboratories | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors |
| CN1863779B (zh) | 2003-10-15 | 2010-05-05 | 宇部兴产株式会社 | 吲唑衍生物 |
| US20050130906A1 (en) | 2003-11-20 | 2005-06-16 | Matier William L. | Amelioration of macular degeneration and other ophthalmic diseases |
| US20050197292A1 (en) | 2004-01-30 | 2005-09-08 | Glennda Smithson | Compositions and methods for treating T-cell mediated pathological conditions |
| BRPI0507807A (pt) | 2004-02-17 | 2007-07-31 | Harvard College | gerenciamento de distúrbios oftalmológicos, incluindo degeneração macular |
| US20050234018A1 (en) | 2004-04-15 | 2005-10-20 | Allergan, Inc. | Drug delivery to the back of the eye |
| WO2006002473A1 (en) | 2004-07-02 | 2006-01-12 | Adelaide Research & Innovation Pty Ltd | Method of controlling damage mediated by alpha, beta-unsaturated aldehydes |
| WO2006049968A1 (en) | 2004-10-28 | 2006-05-11 | Merck & Co., Inc. | Pyrimidine and quinoline potentiators of metabotropic glutamate receptors |
| TW200640443A (en) | 2005-02-23 | 2006-12-01 | Alcon Inc | Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors |
| EP1888548B1 (en) | 2005-05-26 | 2012-08-22 | Neuron Systems, Inc | Quinoline derivative for the treatment of retinal diseases |
| DK2012789T3 (da) * | 2006-04-14 | 2013-12-16 | Prana Biotechnology Ltd | Fremgangsmåde til behandling af aldersrelateret makulær degeneration (AMD) |
| JP2009544631A (ja) | 2006-07-25 | 2009-12-17 | エンビボ ファーマシューティカルズ インコーポレイテッド | キノリン誘導体 |
| CN101889017B (zh) | 2007-10-05 | 2013-11-27 | 奥克塞拉有限公司 | 用于治疗疾病的烷氧基化合物 |
| EP2331534A4 (en) | 2008-08-12 | 2013-01-16 | Sirtris Pharmaceuticals Inc | BENZOXAZOLES, BENZTHIAZOLES AND RELATED ANALOGUES AS MODULATORS OF SIRTUINE |
| WO2010133672A1 (en) | 2009-05-20 | 2010-11-25 | Clanotech Ab | Derivatives of quinoline-3-carboxylic acid and their medical use |
| WO2011008202A1 (en) | 2009-07-15 | 2011-01-20 | Vanderbilt University | Isoketal scavengers and mitigation of disorders involving oxidative injury |
| EP2509596B1 (en) | 2009-12-08 | 2019-08-28 | Case Western Reserve University | Gamma aminoacids for treating ocular disorders |
| JP5885670B2 (ja) | 2009-12-11 | 2016-03-15 | アルデイラ セラピューティクス， インコーポレイテッド | 黄斑変性の処置のための組成物および方法 |
| WO2012097173A2 (en) | 2011-01-12 | 2012-07-19 | Ventirx Pharmaceuticals, Inc. | Substituted benzoazepines as toll-like receptor modulators |
| CN103442735B (zh) | 2011-01-31 | 2016-11-09 | 特米拉公司 | 用于减轻技术领域中所不希望的医学状况的有效要素 |
| EP2948149A4 (en) | 2013-01-23 | 2016-12-14 | Aldeyra Therapeutics Inc | BY TOXIC ALDEHYDIC DISEASES AND TREATMENT |
| CN105228989A (zh) | 2013-01-25 | 2016-01-06 | 奥尔德拉医疗公司 | 黄斑变性治疗中的新颖捕获剂 |
| US10272106B2 (en) | 2014-06-04 | 2019-04-30 | Case Western Reserve University | Compositions and methods of treating diabetic retinopathy |
| WO2016085939A2 (en) | 2014-11-24 | 2016-06-02 | Case Western Reserve University | Compounds and methods of treating ocular disorders |
-
2013
- 2013-12-19 KR KR1020157019397A patent/KR20150118106A/ko not_active Application Discontinuation
- 2013-12-19 CA CA2896032A patent/CA2896032A1/en not_active Abandoned
- 2013-12-19 JP JP2015549717A patent/JP2016503797A/ja not_active Withdrawn
- 2013-12-19 WO PCT/US2013/076592 patent/WO2014100425A1/en active Application Filing
- 2013-12-19 RU RU2015120478A patent/RU2015120478A/ru unknown
- 2013-12-19 EP EP13865015.5A patent/EP2935220A4/en not_active Withdrawn
- 2013-12-19 AU AU2013361314A patent/AU2013361314A1/en not_active Abandoned
- 2013-12-19 MX MX2015007916A patent/MX2015007916A/es unknown
- 2013-12-19 SG SG11201504859YA patent/SG11201504859YA/en unknown
- 2013-12-19 US US14/653,771 patent/US9604997B2/en active Active
- 2013-12-19 CN CN201380067618.3A patent/CN105073714A/zh active Pending
-
2015
- 2015-06-03 IL IL239178A patent/IL239178A0/en unknown
- 2015-06-18 CL CL2015001754A patent/CL2015001754A1/es unknown
-
2016
- 2016-05-09 HK HK16105238.3A patent/HK1217325A1/zh unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11485753B2 (en) | 2012-12-21 | 2022-11-01 | Janssen Pharmaceutica Nv | Substituted nucleosides, nucleotides and analogs thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2015007916A (es) | 2016-04-07 |
| US9604997B2 (en) | 2017-03-28 |
| WO2014100425A1 (en) | 2014-06-26 |
| SG11201504859YA (en) | 2015-07-30 |
| HK1217325A1 (zh) | 2017-01-06 |
| EP2935220A4 (en) | 2016-04-27 |
| US20150344432A1 (en) | 2015-12-03 |
| KR20150118106A (ko) | 2015-10-21 |
| AU2013361314A1 (en) | 2015-07-02 |
| CA2896032A1 (en) | 2014-06-26 |
| JP2016503797A (ja) | 2016-02-08 |
| EP2935220A1 (en) | 2015-10-28 |
| RU2015120478A (ru) | 2017-01-25 |
| CN105073714A (zh) | 2015-11-18 |
| IL239178A0 (en) | 2015-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2015001754A1 (es) | Compuestos derivados de quinolina e isoquinolina; composición farmacéutica y uso para reducir el riesgo de desarrollar una enfermedad o trastorno retinal en el que la acumulación de a2e y/o lipofuscina en el tejido retinal o la señalización de vegf de las células rpe en respuesta al estrés oxidativo. | |
| CL2014003619A1 (es) | Jeringa prellenada que comprende una solución de un antagonista de vegf; empaque blister; uso de la jeringa para tratar enfermedades oculares. | |
| BR112015003376A8 (pt) | composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e usos de quantidade eficiente de composto ou sal farmaceuticamente aceitável do mesmo ou composição farmacêutica | |
| CL2015000295A1 (es) | Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades. | |
| CL2014001994A1 (es) | Polipeptido mimético de apelina sintéticos para el tratamiento e insuficiencia cardiaca; composicion farmacéutica que comprende dicho polipeptido. | |
| BR112013023174A2 (pt) | "compostos derivados de triterpenoide de c4-monometila, composição farmacêutica compreendendo os referidos compostos e uso dos mesmos" | |
| BR112015003125A2 (pt) | ingrediente hidrante cosmético ou7 farmacêutico | |
| BR302012004277S1 (pt) | "configuração aplicada à cápsula" | |
| BR112015003160A2 (pt) | corantes de azaindolina - cianina substituídos por hidroxamato e bioconjugados dos mesmos | |
| BR112014016389A8 (pt) | composições e uso das mesmas para o tratamento de distúrbios e doenças hepáticas | |
| BR112015003345A2 (pt) | protocolo pandêmico para atendimento de emergência | |
| BR302012004276S1 (pt) | "configuração aplicada à cápsula" | |
| BR302012004275S1 (pt) | "configuração aplicada à cápsula" | |
| UA24447S (uk) | М'ясорубка | |
| BR112014020992A2 (pt) | Composto,uso de composto na fabricação de um medicamento e composição farmacêutica | |
| CU24163B1 (es) | Composición farmacéutica oftalmológica tópica que contiene regorafenib | |
| BR302012004274S1 (pt) | "configuração aplicada à cápsula" | |
| BR112017013012A2 (pt) | compostos de indenil, composições farmacêuticas e usos médicos destes | |
| CL2015000537A1 (es) | Siarn y su uso en los métodos y composiciones para el tratamiento y/o prevención de enfermedades de los ojos. | |
| BR112014025416A2 (pt) | AGENTES ANTIMALÁRICOS, COMPOSIÇÃO FARMACEUTICA COMPREENDENDO-OS E USO Dos MESMOS. | |
| BR112014000144A2 (pt) | agentes de controle de coagulação e dispositivos que compreendem os mesmos | |
| BR302012004270S1 (pt) | "configuração aplicada à cápsula" | |
| CL2015001881A1 (es) | Compuesto 4-hidroxi-2-metil-5-(propan-2-iliden)ciclohexil-3-en-1-carbaldehido; uso del compuesto para el tratamiento de la enfermedad de alzheimer; composición farmacéutica; método para preparar la composición. | |
| BR112015014078A2 (pt) | composição farmacêutica oftalmológica tópica que contém regorefenib | |
| DK3313370T3 (da) | Oftalmologisk farmaceutisk sammensætning |